Canada approves second generic Ozempic, slashing diabetes drug costs
Canada approves second generic Ozempic, slashing diabetes drug costs
Canada approves second generic Ozempic, slashing diabetes drug costs
Health Canada has approved a second generic version of Ozempic, making it the first G-7 nation to greenlight generic semaglutide. The medication, produced by Toronto-based Apotex, is cleared for treating Type 2 diabetes in adults. This move follows the earlier approval of the first generic alternative to Novo Nordisk’s brand-name drug. The newly approved generic contains the same active ingredient, semaglutide, as Ozempic. While Ozempic is also widely prescribed off-label for weight loss, its official use remains for diabetes management.
Pricing for generics typically follows a predictable pattern. The first generic version usually costs between 75 and 85 per cent of the brand-name price. Once a second generic enters the market, both versions drop to around 50 per cent of Ozempic’s original cost. With three or more generics available, the price could fall further—to roughly 35 per cent of the brand-name drug’s price. Apotex, a global pharmaceutical firm, now joins the market alongside the first approved generic manufacturer.
The approval of Apotex’s semaglutide introduces more competition into Canada’s diabetes medication market. Lower prices are expected as additional generics become available. This decision positions Canada as the first among major economies to offer generic alternatives to Ozempic.
California judge blocks attempt to expose UCLA's pro-Palestinian event speakers
Free speech wins as a judge halts a campaign to silence Palestinian rights advocates. The decision exposes the dangers of lawfare targeting campus activism.
Vitl's personalised supplements hit Sainsbury's shelves nationwide
From immunity boosts to sleep support, Vitl's science-driven vitamins are now just an aisle away. Could this be the future of personalised wellness?
German nursing care reform faces delay as industry leader demands major revisions
A bold call to halt the reform shakes Berlin. With €1.8 billion at stake and welfare risks looming, will the government rewrite—or rush—ahead?
Stanford's BurgerAI Crafts the Perfect Burger—And It Beats a Big Mac
What if the juiciest, healthiest burger you ever ate was designed by an algorithm? Stanford's AI just proved it's possible—and it's changing fast food forever.